Dear Sir/Madam,This has reference to our letter dated January 28 2026.1) The Board has considered and approved the unaudited Consolidated & Stand-alone Financial Results of the company, for the Quarter ended 31.12.2025 in accordance with the Indian Accounting Standards (IND-AS) as per Companies (Indian Accounting Standards) Rules, 2015.2) Limited Review Report on the Unaudited Standalone and Consolidated Financial Results of the Company, for the quarter ended 31.12.2025 has also been approved.The meeting commenced at 11:00 a.m. and concluded at 11:45 a.m.
Board Meeting Outcome for Outcome Of Board Meeting
View original source (BSE India)Transgene Biotek Limited on 6ix
Earlier from Transgene Biotek
- Transgene Biotek Limited. Press Release Feb 03 2026
- Declaration Under Clause 36 Of Listing Agreement With BSEPROHIBITORY ORDER NO. RRD/SRO/1166/2026/1 - SEBI
- Transgene Biotek Limited. Press Release Jan 12 2026
- Statement Of Deviation & Variation
- Compliance-57 (5): intimation after the end of quarter
Later from Transgene Biotek
- Dear Sir/Madam,This Has Reference To Our Letter Dated January 28 2026.1) The Board Has Considered And Approved The Unaudited Consolidated & Stand-Alone Financial Results Of The Company, For The Quarter Ended 31.12.2025 In Accordance With The Indian A
- Transgene Biotek Limited. Press Release Feb 13 2026
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
- Compliance-57 (4): Prior intimation to the beginning of the quarter
- Intimation Of Non-Applicability Of Regulation 32(1) Of SEBI Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Quarter Ended On 31St March 2026.
Follow Transgene Biotek into a list and get an email when it puts out news.
Follow Transgene Biotek